NO20081289L - Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien - Google Patents

Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien

Info

Publication number
NO20081289L
NO20081289L NO20081289A NO20081289A NO20081289L NO 20081289 L NO20081289 L NO 20081289L NO 20081289 A NO20081289 A NO 20081289A NO 20081289 A NO20081289 A NO 20081289A NO 20081289 L NO20081289 L NO 20081289L
Authority
NO
Norway
Prior art keywords
alkylamino
preparation
trifluoromethoxy
trifluoromethyl
cyano
Prior art date
Application number
NO20081289A
Other languages
English (en)
Norwegian (no)
Inventor
Alistair William Lochead
Frederic Galli
Odile Leclerc
Julien Vache
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36297201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081289(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20081289L publication Critical patent/NO20081289L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20081289A 2005-08-18 2008-03-11 Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien NO20081289L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0508594A FR2889847B1 (fr) 2005-08-18 2005-08-18 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
PCT/FR2006/001911 WO2007020343A1 (fr) 2005-08-18 2006-08-07 Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
NO20081289L true NO20081289L (no) 2008-03-17

Family

ID=36297201

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081289A NO20081289L (no) 2005-08-18 2008-03-11 Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien

Country Status (40)

Country Link
US (3) US7476674B2 (es)
EP (1) EP1922320B1 (es)
JP (1) JP5249758B2 (es)
KR (1) KR101260546B1 (es)
CN (2) CN102558177A (es)
AR (1) AR056461A1 (es)
AT (1) ATE486073T1 (es)
AU (1) AU2006281340B2 (es)
BR (1) BRPI0614796A2 (es)
CA (1) CA2618110C (es)
CR (1) CR9693A (es)
CY (1) CY1111101T1 (es)
DE (1) DE602006017854D1 (es)
DK (1) DK1922320T3 (es)
DO (1) DOP2006000191A (es)
EA (1) EA013601B1 (es)
EC (1) ECSP088182A (es)
ES (1) ES2354833T3 (es)
FR (1) FR2889847B1 (es)
HK (1) HK1125628A1 (es)
HN (1) HN2008000276A (es)
HR (1) HRP20110043T1 (es)
IL (1) IL189014A0 (es)
JO (1) JO2680B1 (es)
MA (1) MA29913B1 (es)
MX (1) MX2008002276A (es)
MY (1) MY145923A (es)
NO (1) NO20081289L (es)
NZ (1) NZ565537A (es)
PE (1) PE20070234A1 (es)
PL (1) PL1922320T3 (es)
PT (1) PT1922320E (es)
RS (1) RS51653B (es)
SI (1) SI1922320T1 (es)
TN (1) TNSN08026A1 (es)
TW (1) TWI322808B (es)
UA (1) UA92360C2 (es)
UY (1) UY29756A1 (es)
WO (1) WO2007020343A1 (es)
ZA (1) ZA200800966B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249307B2 (en) 2011-08-16 2016-02-02 Pierce Biotechnology, Inc. Benzocyanine compounds
US20220347175A1 (en) 2018-07-19 2022-11-03 Sumitomo Dainippon Pharma Co., Ltd. Pyridazinone derivative
US20230109839A1 (en) 2020-01-07 2023-04-13 Sumitomo Pharma Co., Ltd. Therapeutic agent for tauopathies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786770B1 (fr) * 1998-12-04 2001-01-19 Synthelabo Derives de 1,4-diazabicyclo[3.2.2.]nonane, leur preparation et leur application en therapeutique
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
ES2223209B1 (es) 2001-12-11 2005-10-01 Esteve Quimica, S.A. Nuevas formas cristalinas del meloxicam y procedimientos para su preparacion e interconversion.
JP4312456B2 (ja) 2000-10-13 2009-08-12 ニューロサーチ、アクティーゼルスカブ ニコチン性レセプターアゴニスト及びモノアミン作動性物質の組み合わせ作用による情動障害の治療法
FR2834511B1 (fr) * 2002-01-07 2004-02-13 Sanofi Synthelabo Derives de 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, leur preparation et leur application en therapeutique
US6644511B2 (en) 2002-01-11 2003-11-11 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Container for dispensing a dual phase fluid product

Also Published As

Publication number Publication date
TW200738715A (en) 2007-10-16
AU2006281340B2 (en) 2012-04-12
ATE486073T1 (de) 2010-11-15
CN101291933B (zh) 2012-03-14
ECSP088182A (es) 2008-03-26
EP1922320A1 (fr) 2008-05-21
PE20070234A1 (es) 2007-03-26
CN101291933A (zh) 2008-10-22
IL189014A0 (en) 2008-08-07
US20120046298A1 (en) 2012-02-23
NZ565537A (en) 2011-04-29
ZA200800966B (en) 2009-04-29
EA013601B1 (ru) 2010-06-30
MX2008002276A (es) 2008-03-27
CA2618110C (fr) 2014-02-11
EP1922320B1 (fr) 2010-10-27
ES2354833T3 (es) 2011-03-18
AR056461A1 (es) 2007-10-10
KR101260546B1 (ko) 2013-05-06
PL1922320T3 (pl) 2011-04-29
UY29756A1 (es) 2007-03-30
US20090088440A1 (en) 2009-04-02
JP2009504714A (ja) 2009-02-05
AU2006281340A1 (en) 2007-02-22
KR20080034468A (ko) 2008-04-21
DK1922320T3 (da) 2011-02-21
FR2889847B1 (fr) 2007-10-05
WO2007020343A1 (fr) 2007-02-22
CA2618110A1 (fr) 2007-02-22
FR2889847A1 (fr) 2007-02-23
HRP20110043T1 (hr) 2011-02-28
HN2008000276A (es) 2011-03-30
HK1125628A1 (es) 2009-08-14
CY1111101T1 (el) 2015-06-11
EA200800615A1 (ru) 2008-06-30
MY145923A (en) 2012-05-15
CR9693A (es) 2008-03-06
TNSN08026A1 (en) 2009-07-14
BRPI0614796A2 (pt) 2011-04-12
US7476674B2 (en) 2009-01-13
DE602006017854D1 (de) 2010-12-09
MA29913B1 (fr) 2008-11-03
US20080176855A1 (en) 2008-07-24
RS51653B (en) 2011-10-31
TWI322808B (en) 2010-04-01
CN102558177A (zh) 2012-07-11
PT1922320E (pt) 2011-01-19
JO2680B1 (en) 2013-03-03
JP5249758B2 (ja) 2013-07-31
UA92360C2 (en) 2010-10-25
DOP2006000191A (es) 2011-11-15
SI1922320T1 (sl) 2011-02-28
US8076340B2 (en) 2011-12-13
US8557819B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
NO20085169L (no) Krystallinske solvater og komplekser av (1S)-1,5-anhydro-L-C- (3-((fenyl)metyl)fenyl)-D-glucitol derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
NO20090172L (no) Substituert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
NO20070457L (no) Pyrazolderivater
CR10722A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
TWI339659B (en) Aqueous composition comprising thiazole derivative
WO2009118473A3 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
MX2011012057A (es) Derivados de ciclopenta [c] pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su uso en terapéutica.
NO20083955L (no) Nye kromen-2-on-derivater og deres anvendelse som monoaminneurotransmittergjenopptaksinhibitorer
NO20081289L (no) Derivater av 5-pyridazinyl-1-azabicyklo[3.2.1]oktan, deres fremstilling og deres anvendelse i terapien
NO20080458L (no) Derivater av 4,5-diarylpyrrol, fremstilling derav og anvendelsen derav i terapi
BRPI1009497A2 (pt) Derivados de n-[(6-aza-biciclo[3.2.1] oct-5-il)-aril- metil]-heterobenzamida, o respectivo preparo e a respectiva aplicação em terapêutica
RS54736B1 (sr) Postupak za sintezu derivata 3,6-dihidro-1,3,5-triazina
TNSN07472A1 (en) Derivatives of 5-pyridinyl-1-azabicyclo [3.2.1] octane, preparation method thereof and use of same in therapeutics
WO2007057571A3 (fr) Derives de 3-acylindole, leur preparation et leur application en therapeutique comme modulateurs pour les recepteurs cb2
NZ593344A (en) Derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics
TW200942538A (en) 2-benzoylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof
TH81013B (th) อนุพันธ์ (1,5-ไดเฟนิล-1h-ไพแรซอล-3-อิล)ออกแซไดแอซอล, การเตรียมสารและการใช้สารเพื่อรักษาโรค
TH86644B (th) อนุพันธ์ของ 5-พิริดาไซนิล-1-อะซาไบไซโคล[3.2.1]ออกเทน, การเตรียมสารนั้นและการใช้สารนั้นรักษาโรค
TH92041A (th) อนุพันธ์ไพราโซล,สารผสมที่มีสารประกอบดังกล่าวและวิธีการของการใช้

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application